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switching to a combination therapy from monotherapy, regardless of medical 
conditions. Further research is required to evaluate the possible negative aspects 
of FDC drugs.  
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OBJECTIVES: This study reports the results of an economic model predicting 
differences in lifetime cost of health care services consumed following heart 
valve surgery by prosthesis type. This model examines: Mechanical Valve (MV), 
Stented Tissue (ST) and the emerging Transcatheter Valve (replacement surgery 
only) METHODS: The economic model assumes a 55-year-old valve disease 
patient requiring surgery with a 25 year post-surgery life expectancy. Peer 
reviewed journals provided estimates of complication event rates by prosthesis 
type. The model estimated costs for two possible types of valve replacement 
procedure at year 15 for patients receiving initial ST prosthesis: 1) a second ST 
surgery (ST), or 2) a transcatheter valve in valve (ViV) approach. Average annual 
inflation rate of 3% was used. Clinical events included: initial valve surgery; 
thrombotic events; bleeding events; warfarin and monitoring; echo monitoring; 
paravalular leak; endocarditis; pacemaker insertion following valve surgery; re-
operation due to structural valve deterioration; and clinical complications 
following transcatheter procedures. RESULTS: Cumulative costs were estimated 
to be $124,200 using MV during initial surgery; $183,600 using STs; and $478,048 
using ViV. The MV resulted in lower expected health care costs in every year 
versus either ST approaches. The MV choice at the initial surgery results in a 
lifetime cost saving of $59,400 and $353,882 compared to using STs and ViV, 
respectively. The MV approach obtains the majority of its savings after year 15. 
CONCLUSIONS: Our model estimates changing initial prosthesis choice to the 
MV in the estimated 20,000 ST valve surgeries performed annually in the U.S. 
among patients below age 65 would result in approximately $1.2 billion lifetime 
reduction in direct health care expenditures over the next 25 years, The majority 
of savings occur when these patients would be Medicare Beneficiaries.  
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OBJECTIVES: We examined predictors of high cost for abdominal aortic 
aneurysm (AAA) repair in order to identify patients who are likely to require 
more intensive treatments. In general, younger, healthier patients with 
unfavorable anatomy are good candidates for Open AAA repair while older 
patients with significant comorbidities and favorable anatomy have better 
results when treated with the less invasive endovascular aneurysm repair (EVAR) 
procedure. Indeed, a sizable number of patients present with AAA who could be 
treated safely following either modality. METHODS: A dataset of elective AAA 
repairs totaling 389 Fletcher Allen Health Care patients (230 EVAR, 159 OPEN) was 
analyzed retrospectively over the time period January 1, 2003 through December 
31, 2011. Direct and indirect costs were obtained along with length of stay (LOS) 
and other clinical and behavioral parameters. Models to predict being in the 
upper quartile of cost were developed using logistic regression. RESULTS: 
Significant predictors of being in the upper quartile of costs for Open patients 
were history of treated COPD, previous bypass surgery, transfer from hospital, 
and age >70, with area under ROC=0.726. Predictors for EVAR patients were 
presence of iliac aneurysm(s), CABG/PTCA within the past 5 years, ejection 
fraction ≤30%, on beta blocker, creatinine ≥1.5mg/dl, and current smoker, with 
area under ROC=0.784. For EVAR patients, who had an average LOS of only 1-2 
days, total costs ranged from $21,904 to $47,511. For Open patients, who had an 
average LOS of 5-7 days, these figures ranged from $13,549 to $35,685 in constant 
dollars. CONCLUSIONS: This wide range of total cost invites the introduction of 
resource utilization tools based on cost predictors that can optimize clinical 
outcomes and reduce costs at the individual patient level.  
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OBJECTIVES: Platinum chromium everolimus-eluting stents (PtCr-EES) were 
compared to cobalt chromium everolimus-eluting stents (CoCr-EES) in the 
randomized controlled PLATINUM trial. Clinical outcomes including rates of 
target vessel revascularization (TVR), myocardial infarction (MI), and cardiac 
death have been reported through 2 years (n=1507), with 3 year data to come. An 
economic analysis was performed to assess the cost-effectiveness of PtCr-EES 
versus CoCr-EES accounting for stent reimbursement practice, in which payers 
reimburse by procedure but hospitals bear the direct cost of stents. METHODS: A 
Markov model was used to compare costs from payer (Medicare) and hospital 
perspectives of PtCr-EES versus CoCr-EES over two years, based. The model 
explicitly accounted for costs (2013) of differences in index procedure and long-
term cardiac events. Payer costs for the index procedure were increased only for 
those bailout (unplanned) stents associated with major complicating conditions 
(MCC; aortic dissections or extended length of stay), while hospital costs 
reflected all stents used (bailout or planned). Similarly, those MIs concurrent 
with TVR and all stent thromboses were modeled as MCCs of the TVRs, not 
separate events. RESULTS: PtCr-EES was cost saving versus CoCr-EES by 
$277/patient from a payer perspective, due to reduced costs for bailout stenting 
during the index procedure (3.1% vs. 4.2%) and TVR over 2 years (4.3% versus 
5.4%). Probabilistic sensitivity analysis found PtCr-EES was economically 
dominant (more effective and less costly) in 81% of replications. From a hospital 
perspective, PtCr-EES saved an additional $151/patient in reduced stent 
acquisition costs. A detailed costing analysis would be required to determine 
how much of the $277/patient reduction in reimbursement reflects reduced 
hospital costs, and thus total societal savings. CONCLUSIONS: PtCr-EES was 
found to be cost saving versus CoCr-EES from both payer and hospital 
perspectives, primarily due to reduced TVR over 2 years. Total societal savings 
may be up to $428/patient.  
 
PCV50  
EVALUATING THE AVERAGE REINTERVENTIONS, REINTERVENTION COSTS 
AND TOTAL COSTS FOR A HEPARIN-BONDED EPTFE STENT-GRAFT IN 
PATIENTS WITH ATHEROSCLEROTIC DISEASE OF THE SFA  
Mohr BA1, Martinell MJ2, Sheen AL1 
1W.L. Gore & Associates, Inc., Phoenix, AZ, USA, 2W.L. Gore & Associates, Inc., Flagstaff, AZ, 
USA  
OBJECTIVES: We examined the average number of reinterventions, average 
reintervention costs (ARC), and the average total costs (ATC) for the latest 
iteration of a heparin-bonded ePTFE Stent-Graft versus a bare metal stent (BMS) 
in patients treated for atherosclerotic disease of the superficial femoral artery 
(SFA). ATC includes costs for the initial implant, reinterventions, and follow-up 
care. METHODS: As previously reported by Saxon (2011) and Ansel (2011), two 
independent clinical studies of the Stent-Graft were recently completed. One-
year results from the multicenter, single-arm, VIPER trial were compared to the 
one-year results of the BMS arm from the three-year, multicenter, randomized 
VIBRANT trial. The Stent-Graft used in the VIPER trial is the latest iteration of the 
device in use today. Patient characteristics were similar in both trials. Cost data 
from the Centers for Medicare and Medicaid Services was used to estimate ARC 
and ATC for all patients, and secondarily, for patients oversized ≤20% at the 
proximal edge of the Stent-Graft (instructions for use recommend 5-20% 
oversizing). RESULTS: The Stent-Graft group trended toward fewer 
reinterventions per patient than the BMS group (0.36 vs. 0.63, P=0.15), lower ARC 
($3,143 vs. $4,346, P=0.38), and higher ATC ($16,482 vs. $14,987, P=0.36) through 
one year follow-up. Patients oversized ≤20% trended toward fewer 
reinterventions per patient (0.21 vs. 0.63, P=0.08), lower ARC ($1,588 vs. $4,346, 
P=0.05), which was statistically significant, and lower ATC ($14,524 vs. $14,987, 
P=0.78) versus the BMS. CONCLUSIONS: Based on the comparison of one-year 
follow up data, the Stent-Graft trended toward reducing reinterventions and ARC 
for all patients being treated for atherosclerotic SFA disease compared to BMS. 
When oversized ≤20% at the proximal edge, the Stent-Graft reduced ARC 
(statistically significant finding) and trended toward reducing reinterventions 
and ATC. Long-term follow up will be needed to measure the benefits beyond 
one year for all patients.  
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OBJECTIVES: Estimate the real-world economic impact of switching from 
metoprolol, the most commonly prescribed β-blocker for hypertension in the US, 
to nebivolol, a novel well-tolerated β-blocker with high β1 selectivity and 
vasodilatory properties, for hypertension treatment. METHODS: Retrospective 
database analysis with a pre and post study design was conducted using 
MarketScan database (2007-2011). Hypertensive patients continuously treated 
with metoprolol for at least six months (pre-period) and then switched to 
nebivolol for at least six months (post-period) were identified. The first nebivolol 
dispensing date was defined as the index date for switching. Data were collected 
for the two six-month periods pre- and post- switching. Monthly health care 
resource utilization and health care costs pre and post switching were calculated 
and compared using Wilcoxon and paired t-tests. Medical costs at different years 
were inflated to the 2011 dollar using medical component consumer price index. 
RESULTS: A total of 2259 patients, with a mean age of 60, met the selection 
criteria. Among them, 52% were male, 37% had cardiovascular (CV) disease. After 
patients switched to nebivolol, there were statistically significant reductions in 
the number of all-cause hospitalization (p<0.01), CV related hospitalization 
(p<0.01), outpatient visits (p<0.01), and CV related emergency room (ER) visits 
(p=0.01). Monthly inpatient costs reduced $106 (p<0.01), while monthly drug cost 
increased $49 (p<0.01). There were reductions on costs of outpatient and ER 
visits, but the differences were not statistically significant. Overall health care 
cost reduced $63 per patient per month. Sensitivity analysis on length of 
medication exposure found similar results. CONCLUSIONS: This real-world 
study finds that patients who switched from metoprolol to nebivolol had a lower 
overall health care cost after switching.  
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